Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

NCT05776875 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT05776875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05776875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Terminated
Start date
June 7, 2023
Completion date
December 5, 2024
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bclc stage b hepatocellular carcinoma, hepatocellular carcinoma